



FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV304411999US
Express Mail Label Number

May 22, 2006
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

WHITNEY ET AL.

APPLICATION NO: 10/600,816

FILED: JUNE 20, 2003

FOR: IDENTIFICATION AND MODULATION OF A G-PROTEIN COUPLED
RECEPTOR (GPCR), RAI3, ASSOCIATED WITH CHRONIC
OBSTRUCTIVE PULMONARY DISEASE (COPD) AND NF-KB AND
E-SELECTIN REGULATION

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants believe this paper is being filed before the mailing date of a first Office Action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-3880.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.


Some of the listed references were cited in a search report in a corresponding PCT International application. Copies of these references and the search report are enclosed herewith.

Also, copies of the other cited references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
(609) 252-5289



Stephen C. D'Amico
Agent for Applicants
Reg. No. 46,652

Date: May 22, 2006

FORM PTO-1449
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
D0251 NP
APPLICATION NO.
10/600,816
APPLICANT
WHITNEY ET AL.
FILING DATE
JUNE 20, 2003

Group

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA	5,618,717	4/8/97	Wei, et al.			
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES NO	
	AM	WO01/42467 A2	6/14/01	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AN						<input type="checkbox"/>	<input type="checkbox"/>
	AO						<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	Aggarwal, Bharat B., "Apoptosis and Nuclear Factor- κ B: A Tale of Association and Dissociation", Biochem. Pharmacol., Vol. 60, pp. 1033-1039 (2000)
	AS	Baldi, et al., "Critical Role for Lysines 21 and 22 in Signal-induced, Ubiquitin-mediated Proteolysis of I κ B- α ", Vol. 271, pp. 376-379 (1996)
	AT	Baeuerle, et al., "NF- κ B: Ten Years After", Cell. Vol. 87, pp. 13-20 (1996)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
D0251 NP
APPLICATION NO.
10/600,816
APPLICANT
WHITNEY ET AL.
FILING DATE
JUNE 20, 2003

Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

2AA	Baldwin, Albert S., "The NF- κ B And I κ B Proteins: New Discoveries and Insights", Annu. Rev. Immunol., Vol. 14, pp. 649-681 (1996)
2AB	Baldwin, Albert S., "Control of oncogenesis and cancer therapy resistance by the transcription factor NF- κ B", J. Clin. Invest., Vol. 107(3), pp. 241-246 (2001)
2AC	Baldwin, Albert S., Jr., "The transcription factor NF- κ B and human disease", J. Clin. Invest., Vol. 107(1), pp. 3-6 (2001)
2AD	Basu, et al., "The DNA-Dependent Protein Kinase Participates in the Activation of NF κ B Following DNA Damage", Biochem. Biophysical Res. Comm., Vol. 247, pp. 79-83 (1998)
2AE	Baud, et al., "Signal transduction by tumor necrosis factor and its relatives", TRENDS Cell Biol., Vol. 11(9), pp. 372-377 (2001)
2AF	Blahos, et al., "A Novel Site on the G α -protein That Recognizes Heptahelical Receptors", Vol. 275(5), pp. 3262-3269 (2001)
2AG	Bockaert, et al., "G Protein-Coupled Receptors: Dominant Players in Cell-Cell Communication", Int. Rev. Cyt., Vol. 212, pp. 63-132 (2002)
2AH	Brauner-Osborne, et al., "Sequence and Expression Pattern of a Novel Human Orphan G-Protein-Coupled Receptor, GPRC5B, a Family C Receptor with a Short Amino-Terminal Domain", Genomics, Vol. 65, pp. 121-128 (2000)
2AI	Brauner-Osborne, et al., "Cloning and characterization of a human orphan family C G-protein coupled receptor GPRC5D", Biochimica Biophysica Acta, Vol. 1518, pp. 237-248 (2001)
2AJ	Brown, et al., "Control of I κ B- α Proteolysis by Site-Specific, Signal-Induced Phosphorylation", Science, Vol. 267, pp. 1485-1488 (1995)
2AK	Bunzow, et al., "Cloning and expression of a rat D ₂ dopamine receptor cDNA", Nature, Vol. 336, pp. 783-787 (1998)
2AL	Cafferata, et al., "Identification by Differential Display of a mRNA Specifically Induced by 12-O-Tetradecanoylphorbol-13-Acetate (TPA) in T84 Human Colon Carcinoma Cells", Cellular Molec. Biol., Vol. 42(5), pp. 797-804 (1996)
2AM	Chalmers, et al., "The Use of Constitutively Active GPCRs In Drug Discovery and Functional Genomics", Nature Reviews, Vol. 1, pp. 599-608 (2002)
2AN	Chen, et al., "Use of Constitutive G Protein-Coupled Activity for Drug Discovery", Molec. Pharm., Vol. 57, pp. 125-134 (2000)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE**INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)

ATTY. DOCKET NO.
D0251 NP
APPLICATION NO.
10/600,816
APPLICANT
WHITNEY ET AL.
FILING DATE
JUNE 20, 2003

Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

3AA	Chen, et al., "Constitutive receptor systems for drug discovery", J. Pharmacol Toxicol, Vol. 42, pp. 199-206 (1999)
3AB	Cheng, et al., "Molecular Cloning and Characterization of a Novel Retinoic Acid-inducible Gene That Encodes a Putative G Protein-coupled Receptor", J. Biol. Chem., Vol. 273(52), pp. 35008-35015 (1998)
3AC	Christman, et al., "The Role of Nuclear Factor- κ B in Pulmonary Diseases", Chest, Vol. 117, pp. 1482-1487 (2000)
3AD	Civelli, Olivier, "Functional genomics: the search for novel neurotransmitters and neuropeptides", FEBS Letters, Vol. 430, pp. 55-58 (1998)
3AE	Day, et al., "Bleomycin upregulates expression of γ -glutamylcysteine synthetase in pulmonary artery endothelial cells", Am. J. Physiol. Lung Cell Mol. Physiol., Vol. 282, pp. L1349-L1357 (2002)
3AF	deLigt, et al., "Inverse agonism at G protein-coupled receptors: (patho) physiological relevance and implications for drug discovery", British J. Pharmacol, Vol. 130, pp. 1-12 (2000)
3AG	Feng, et al., "HIV-1 Entry Cofactor: Functional cDNA Cloning of a Seven-Transmembrane, G Protein-Coupled Receptor", Science, Vol. 272, pp. 872-877 (1996)
3AH	Finco, et al., "Inducible phosphorylation of I κ B α is not sufficient for its dissociation from NF- κ B and is inhibited by protease inhibitors", PNAS, Vol. 91, pp. 11884-11888 (1994)
3AI	Geysen, et al., "Use of peptide synthesis to probe viral antigens for epitopes to a resolution of a single amino acid", PNAS, Vol. 81, pp. 3998-4002 (1984)
3AJ	Ghosh, et al., "NF- κ B and Rel Proteins: Evolutionarily Conserved Mediators of Immune Responses", Annu. Rev. Immunol., Vol. 16, pp. 225-260 (1998)
3AK	Guijarro, et al., "Transcription factor- κ B (NF- κ B) and renal disease", Kidney Int'l., Vol. 59, pp. 415-424 (2001)
3AL	Gurujeyalakshmi, et al., "Taurine and Niacin Block Lung Injury and Fibrosis by Down-Regulating Bleomycin-Induced Activation of Transcription Nuclear Factor - κ B in Mice", J. Pharm. Exper. Ther., Vol. 293(1), pp. 82-90 (2000)
3AM	Hinuma, et al., "The quest for novel bioactive peptides utilizing orphan seven-transmembrane-domain receptors", J. Mol. Med., Vol. 77, pp. 495-504 (1999)
3AN	Horn, et al., "The Interaction of Class B G Protein-Coupled Receptors with their Hormones", Receptors Channels, Vol. 5, pp. 305-314 (1998)

EXAMINER**DATE CONSIDERED**

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE**INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)

ATTY. DOCKET NO.
D0251 NP
APPLICATION NO.
10/600,816
APPLICANT
WHITNEY ET AL.
FILING DATE
JUNE 20, 2003

Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

4AA	Horn, et al., "G protein-coupled receptors <i>in silico</i> ", J. Mol. Med., Vol. 76, pp. 464-468 (1998)
4AB	Howard, et al., "Orphan G-protein-coupled receptors and natural ligand discovery", Vol. 22, pp. 132-140 (2001)
4AC	Hubbard, et al., "Activation of NF- κ B-dependent gene expression by silica in lungs of luciferase reporter mice", Am. J. Physiol. Lung Cell Mol. Physiol., Vol. 282, pp. L968-L975 (2002)
4AD	Johnson, et al., "The G-Protein Family and Their Interaction with Receptors", Endocrine Rev., Vol. 10(3), pp. 317-331 (1989)
4AE	Knappik, et al., "Fully Synthetic Human Combinatorial Antibody Libraries (HuCAL) Based on Modular Consensus Frameworks and CDRs Randomized with Trinucleotides", J. Mol. Biol., Vol. 296, pp. 57-86 (2000)
4AF	Kobilka, et al., "Cloning, Sequencing, and Expression of the Gene Coding for the Human Platelet α_2 -Adrenergic Receptor", Science, Vol. 238, pp. 650-656 (1987)
4AG	Kobilka, et al., "cDNA for the human β_2 -adrenergic receptor: A protein with multiple membrane-spanning domains and encoded by a gene whose chromosomal location is shared with that of the receptor for platelet-derived growth factor", PNAS, Vol. 84, pp. 46-50 (1987)
4AH	Kohler, et al., "Continuous cultures of fused cells secreting antibody of predefined specificity", Nature, Vol. 256, pp. 495-497 (1975)
4AI	Leurs, et al., "Agonist-independent regulation of constitutively active G-protein-coupled receptors", TIBS, Vol. 23, pp. 418-422 (1998)
4AJ	Leurs, et al., "Constitutive activity of G protein coupled receptors and drug action", Pharmaceutica Acta Helveticae, Vol. 74, pp. 327-331 (2000)
4AK	Love, et al., "Vitamin A, differentiation and cancer", Curr. Opin. Cell Biol., Vol., 6, pp. 825-831 (1994)
4AL	International Human Genome Sequencing Consortium, "Initial sequencing and analysis of the human genome", Nature, Vol. 409, pp. 860-921 (2001)
4AM	Massaro, et al., "Retinoic acid treatment partially rescues failed septation in rats and in mice", Am. J. Physiol. Lung Cell Mol. Physiol., Vol. 278, pp. L955-L960 (2000)
4AN	Milligan, et al., "G ₁₆ as a universal G protein adapter: implications for agonist screening strategies", TIPS, Vol. 17, pp. 235-237 (1996)

EXAMINER**DATE CONSIDERED**

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE**INFORMATION DISCLOSURE CITATION***(Use several sheets if necessary)*ATTY. DOCKET NO.
D0251 NP
APPLICATION NO.
10/600,816
APPLICANT
WHITNEY ET AL.
FILING DATE
JUNE 20, 2003

Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

5AA	Milligan, et al., "Chimaeric Gα proteins: their potential use in drug discovery", TIPS, Vol. 20, pp. 118-124 (1999)
5AB	Morriss-Kay, et al., "Embryonic development and pattern formation", Faseb J., Vol. 10, pp. 961-968 (1996)
5AC	Nagahata, et al., "Identification of RA13 as a therapeutic target for breast cancer", Endocrine-Rel. Cancer, Vol. 12, pp. 65-73 (2005)
5AD	Needleman, et al., "A General Method Applicable to the Search for Similarities in the Amino Acid Sequence of Two Proteins", J. Mol. Biol., Vol. 48, pp. 443-453 (1970)
5AE	Offermanns, et al., "Gα ₁₅ and Gα ₁₆ Couple a Wide Variety of Receptors to Phospholipase C", J. Biol. Chem., Vol. 270(25), pp. 15175-15180 (1995)
5AF	Pierce, et al., "Seven-Transmembrane Receptors", Nature Revs. Molec. Cell. Biol., Vol. 3, pp. 639-650 (2002)
5AG	Robbins, et al., "Localisation of the GPRC5B receptor in the rat brain and spinal cord", Molec. Brain Res., Vol. 106, pp. 136-144 (2002)
5AH	Robbins, et al., "Molecular Cloning and Characterization of Two Novel Retinoic Acid-Inducible Orphan G-Protein-Coupled Receptors (GPRC5B and GPRC5C), Genomics, Vol. 67, pp. 8-18 (2000)
5AI	Roff, et al., "Role of IκBα Ubiquitination in Signal-induced Activation of NF-κB in Vivo", J. Biol. Chem., Vol. 271(13), pp. 7844-7850 (1996)
5AJ	Sacks, et al., "Retinoic Acid Inhibition of a Head and Neck Multicellular Tumor Spheroid Model", Head Neck, Vol. 11, pp. 219-225 (1989)
5AK	Siebenlist, et al., "Structure, Regulation and Function of NF-κB", Ann. Rev. Cell Biol., Vol. 10, pp. 405-455 (1994)
5AL	Silverman, et al., "NF-κB signaling pathways in mammalian and insect innate immunity", Genes Develop., Vol. 15, pp. 2321-2342 (2001)
5AM	Simon, et al., "Diversity of G Proteins in Signal Transduction", Science, Vol. 252, pp. 802-808 (1991)
5AN	Strebel, et al., "Characterization of Foot-and-Mouth Disease Virus Gene Products with Antisera Against Bacterially Synthesized Fusion Proteins", J. Virol, pp. 983-991 (1986)

EXAMINER**DATE CONSIDERED**

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE**INFORMATION DISCLOSURE CITATION***(Use several sheets if necessary)*ATTY. DOCKET NO.
D0251 NP
APPLICATION NO.
10/600,816
APPLICANT
WHITNEY ET AL.
FILING DATE
JUNE 20, 2003

Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

6AA	Sueoka, et al., "Molecular Pathogenesis of Interstitial Pneumonitis with TNF- α Transgenic Mice", Cytokine, Vol. 10(2), pp. 124-131 (1998)
6AB	Takeyama, et al., "Oxidative Stress Causes Mucin Synthesis Via Transactivation of Epidermal Growth Factor Receptor: Role of Neutrophils", J. Immunol., Vol. 164, pp. 1546-1552 (2000)
6AC	Thornberry, et al., "Caspases: Enemies Within", Science, Vol. 281, pp. 1312-1316 (1998)
6AD	Valen, et al., "Nuclear Factor Kappa-B and the Heart", J. Amer. Coll. Cardiology, Vol. 38(2), pp. 307-314 (2001)
6AE	Venter, et al., "The Sequence of the Human Genome", Science, Vol. 291, pp. 1304-1351 (2001)
6AF	Weil, et al., "Regulation of I κ B β Degradation", J. Biol. Chem., Vol. 272(15), pp. 9942-9949 (1997)
6AG	Whiteside, et al., "I kappa B epsilon, a novel member of the I κ B family, controls RelA and cRel NF- κ B activity", Embo J., Vol. 16(5), pp. 1413-1426 (1997)
6AH	Wu, et al., "Integrative Genomics Revealed RA13 Is a Cell Growth-promoting Gene and a Novel P53 Transcriptional Target", J. Biol. Chem., Vol. 280(13), pp. 12935-12943 (2005)
6AI	Zlokarnik, et al., "Quantitation of Transcription and Clonal Selection of Single Living Cells with β -Lactamase as Reporter", Science, Vol. 279, pp. 84-88 (1998)
6AJ	NCBI Entrez Accession No. NM_003979 (gi:63252917), Wu, et al., September 24, 2005
6AK	NCBI Entrez Accession No. NM_014707 (gi:7662279), Han, et al., March 19, 2006
6AL	NCBI Entrez Accession No. NM-058176 (gi:17158038), Han, et al., March 19, 2006
6AM	NCBI Entrez Accession No. NM_058177 (gi:17158040), Han, et al., March 19, 2006
6AN	

EXAMINER**DATE CONSIDERED**

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.